Swift C G, Lee D R, Maskrey V L, Yisak W, Jackson S H, Tiplady B
Department of Health Care of the Elderly, King's College School of Medicine and Dentistry, London, UK.
J Psychopharmacol. 1999;13(2):159-65. doi: 10.1177/026988119901300208.
Phenothiazines are widely used in older patients, but little experimental work has been carried out in this age group. Two groups of healthy volunteers, a younger group (Y: six males and six females, aged 20-42 years) and an older group (O: six males and eight females, aged 65-77 years) took part in a randomized double-blind three-period crossover study in which they received by mouth single doses of thioridazine (Y: 50 mg; O: 25 mg) remoxipride (Y: 100 mg; O: 50 mg) or placebo. Measures of central nervous system (CNS) and haemodynamic function were carried out before drug administration and at 1.5-h intervals up to 9 h post-dose, and blood samples were collected over a 24-h period. No significant differences in dose-corrected pharmacokinetic variables were found between the two groups. There was evidence of marked CNS depressant effects of thioridazine from both objective and subjective measures. The effects for remoxipride were similar, though generally less marked. After allowance was made for dose, there was little indication of any difference in degree of CNS depression between the two age groups. Haemodynamic measures showed orthostatic reductions in blood pressure with thioridazine which were particularly marked in the older group, who also showed lower compensatory increases in pulse rate. These results indicate potential problems with orthostatic hypotension with thioridazine in older patients. CNS depression may also be a problem, especially in patients with compromised cholinergic function.
吩噻嗪类药物在老年患者中广泛使用,但针对该年龄组开展的实验研究很少。两组健康志愿者,一组较年轻(Y组:6名男性和6名女性,年龄20 - 42岁),另一组为老年组(O组:6名男性和8名女性,年龄65 - 77岁)参与了一项随机双盲三阶段交叉研究,他们口服单剂量的硫利达嗪(Y组:50毫克;O组:25毫克)、瑞莫必利(Y组:100毫克;O组:50毫克)或安慰剂。在给药前以及给药后长达9小时的时间内,每隔1.5小时进行一次中枢神经系统(CNS)和血流动力学功能测量,并在24小时内采集血样。两组之间在剂量校正后的药代动力学变量方面未发现显著差异。从客观和主观测量结果来看,都有证据表明硫利达嗪具有明显的中枢神经系统抑制作用。瑞莫必利的作用类似,尽管通常不太明显。在考虑剂量因素后,几乎没有迹象表明两个年龄组之间中枢神经系统抑制程度存在差异。血流动力学测量显示,硫利达嗪会导致体位性血压降低,在老年组中尤为明显,老年组的脉搏率代偿性增加也较低。这些结果表明,老年患者使用硫利达嗪可能存在体位性低血压的潜在问题。中枢神经系统抑制也可能是一个问题,尤其是在胆碱能功能受损的患者中。